City

Shanghai (2)

Condition

Anti-PD-1 (2)

Neoadjvant Therapy (2)

Oral Squamous Cell Carcinoma (2)

Anti-VEGFR (1)

Chemotherapy (1)

Overall Status

Recruiting (2)

Sign in for free

Phase

phase 2 (1)

phase 2/phase 3 (1)

Sponsor

Shanghai Jiao Tong University School of Medicine (2)

Collaborator

Intervention

5-fluorouracil (1)

albumin paclitaxel (1)

apatinib (anti-vegfr inhibitor) (1)

camrelizumab (anti-pd-1 inhibitor) (1)

cisplatin (1)

docetaxel (1)

toripalimab (anti-programmed death-1 inhibitor) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (2)

neoadjvant therapy

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting

Oral Squamous Cell Carcinoma
+3 more

Camrelizumab (anti-PD-1 inhibitor)
Apatinib (anti-VEGFR inhibitor)

Shanghai, Shanghai, China

Ninth People's Hospital, Shanghai Jiao Tong University School of

Oct 8, 2022

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),

Recruiting

Oral Squamous Cell Carcinoma
+3 more

Toripalimab (anti-programmed death-1 inhibitor)
+4 more

Shanghai, Shanghai, China

Ninth People's Hospital, Shanghai Jiao Tong University School of

Oct 8, 2022